FATE250117C4000
- 0.24
- 0.000.00%
Fate Therapeutics Newsroom
Barclays Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $10
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Maintains Target Price $3
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits
Express News | Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus
TD Cowen Maintains Fate Therapeutics(FATE.US) With Hold Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6
Express News | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Taps Bob Valamehr to Be CEO
Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
Express News | Fate Therapeutics Inc - Bob Valamehr to Become President and CEO Jan 1, 2025
Express News | Fate Therapeutics Inc - Scott Wolchko to Retire as President and CEO Dec 31, 2024
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
Fate Therapeutics to Present at Upcoming December Investor Conferences
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Express News | Fate Therapeutics Inc : BofA Global Research Raises to Neutral From Underprform
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $10
Needham Reiterates Hold on Fate Therapeutics